{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:34:03Z","timestamp":1794065643407,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12035-022-03150-5","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T02:02:43Z","timestamp":1670551363000},"page":"1486-1498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["CRISPR\/Cas9 Mediated Therapeutic Approach in Huntington\u2019s Disease"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-8246","authenticated-orcid":false,"given":"Suleyman Serdar","family":"Alkanli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3745-8838","authenticated-orcid":false,"given":"Nevra","family":"Alkanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-091X","authenticated-orcid":false,"given":"Arzu","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-5164","authenticated-orcid":false,"given":"Isil","family":"Albeniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"2","key":"3150_CR1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s12035-021-02638-w","volume":"59","author":"L Guan","year":"2022","unstructured":"Guan L, Han Y, Yang C, Lu S, Du J, Li H, Lin J (2022) CRISPR-Cas9-mediated gene therapy in neurological disorders. Mol Neurobiol 59(2):968\u2013982","journal-title":"Mol Neurobiol"},{"key":"3150_CR2","doi-asserted-by":"publisher","first-page":"180177","DOI":"10.1098\/rsob.180177","volume":"9","author":"Y-Y Wu","year":"2019","unstructured":"Wu Y-Y, Chiu F-L, Yeh C-S et al (2019) Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease. Open Biol 9:180177","journal-title":"Open Biol"},{"key":"3150_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JHD-160222","volume":"6","author":"TB Malankhanova","year":"2017","unstructured":"Malankhanova TB, Malakhova AA, Medvedev SP et al (2017) Modern genome editing technologies in Huntington\u2019s disease research. J Huntingt Dis 6:19\u201331","journal-title":"J Huntingt Dis"},{"key":"3150_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/brainsci10010043","volume":"10","author":"A Kumar","year":"2020","unstructured":"Kumar A, Kumar V, Singh K et al (2020) Therapeutic advances for Huntington\u2019s disease. Brain Sci 10:43","journal-title":"Brain Sci"},{"key":"3150_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1087057104272663","volume":"10","author":"P-Q Liu","year":"2005","unstructured":"Liu P-Q, Tan S, Mendel MC et al (2005) Isogenic human cell lines for drug discovery: regulation of target gene expression by engineered zinc-finger protein transcription factors. J Biomol Screen 10:304\u2013313","journal-title":"J Biomol Screen"},{"key":"3150_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/jcm3041402","volume":"3","author":"K Freude","year":"2014","unstructured":"Freude K, Pires C, Hyttel P et al (2014) Induced pluripotent stem cells derived from Alzheimer\u2019s disease patients: the promise, the hope and the path ahead. J Clin Med 3:1402\u20131436","journal-title":"J Clin Med"},{"key":"3150_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fnins.2017.00628","volume":"11","author":"A Al-Gharaibeh","year":"2017","unstructured":"Al-Gharaibeh A, Culver R, Stewart AN et al (2017) Induced pluripotent stem cell-derived neural stem cell transplantations reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of Huntington\u2019s disease. Front Neurosci 11:628","journal-title":"Front Neurosci"},{"key":"3150_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101:801\u2013819","journal-title":"Neuron"},{"issue":"22","key":"3150_CR9","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1093\/hmg\/ddx327","volume":"26","author":"Y Liu","year":"2017","unstructured":"Liu Y, Qiao F, Leiferman PC et al (2017) FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington\u2019s disease and their derived neural cells. Hum Mol Genet 26(22):4416\u20134428","journal-title":"Hum Mol Genet"},{"key":"3150_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lfs.2018.07.030","volume":"209","author":"MM Golas","year":"2018","unstructured":"Golas MM (2018) Human cellular models of medium spinyneuron development and Huntington disease. Life Sci 209:179\u2013196","journal-title":"Life Sci"},{"key":"3150_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","volume":"7","author":"A Neueder","year":"2017","unstructured":"Neueder A, Landles C, Ghosh R et al (2017) The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients. Sci Rep 7:1307","journal-title":"Sci Rep"},{"key":"3150_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccaco","year":"2010","unstructured":"Zuccaco C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90:905\u2013981","journal-title":"Physiol Rev"},{"key":"3150_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-3-642-45106-5_14","volume":"220","author":"C Zuccato","year":"2014","unstructured":"Zuccato C, Cattaneo E (2014) Huntington\u2019s disease. Handb Exp Pharmacol 220:357\u2013409","journal-title":"Handb Exp Pharmacol"},{"key":"3150_CR14","first-page":"15005","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis 1:15005","journal-title":"Nat Rev Dis"},{"key":"3150_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83\u201398","journal-title":"Lancet Neurol"},{"key":"3150_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/B978-0-12-381328-2.00015-8","volume":"98","author":"L Jones","year":"2011","unstructured":"Jones L, Hughes A (2011) Pathogenic mechanisms in Huntington\u2019s disease. Int Rev Neurobiol 98:373\u2013418","journal-title":"Int Rev Neurobiol"},{"key":"3150_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neuron.2017.03.023","volume":"94","author":"JC Grima","year":"2017","unstructured":"Grima JC, Daigle JG, Arbez N et al (2017) Mutant huntingtin disrupts the nuclear pore complex. Neuron 94:93-107.e6","journal-title":"Neuron"},{"key":"3150_CR18","first-page":"473","volume":"1780","author":"G Vachey","year":"2018","unstructured":"Vachey G, D\u00e9glon N (2018) CRISPR\/Cas9-mediated genome editing for Huntington\u2019s disease. Methods Mol Biol 1780:473\u2013481","journal-title":"Methods Mol Biol"},{"issue":"4","key":"3150_CR19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3892\/etm.2016.3566","volume":"12","author":"WJ Huang","year":"2016","unstructured":"Huang WJ, Chen WW, Zhang X (2016) Huntington\u2019s disease: molecular basis of pathology and status of current therapeutic approaches. Exp Ther Med 12(4):1951\u20131956. https:\/\/doi.org\/10.3892\/etm.2016.3566","journal-title":"Exp Ther Med"},{"key":"3150_CR20","first-page":"1353","volume":"98","author":"ES Cankurtaran","year":"2006","unstructured":"Cankurtaran ES, Ozalp E, Soygur H et al (2006) Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease. J Natl Med Assoc 98:1353\u20131355","journal-title":"J Natl Med Assoc"},{"key":"3150_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585\u2013595","journal-title":"Nat Genet"},{"key":"3150_CR22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168:960\u2013976","journal-title":"Cell"},{"key":"3150_CR23","doi-asserted-by":"publisher","first-page":"ra103","DOI":"10.1126\/scisignal.2005633","volume":"7","author":"WM Pryor","year":"2014","unstructured":"Pryor WM, Biagioli M, Shahani N et al (2014) Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington\u2019s disease. Sci Signal 7:ra103","journal-title":"Sci Signal"},{"key":"3150_CR24","first-page":"111","volume":"68","author":"J Andrich","year":"2004","unstructured":"Andrich J, Saft C, Gerlach M et al (2004) Coenzyme Q10 serum levels in Huntington\u2019s disease. J Neural Transm 68:111\u2013116","journal-title":"J Neural Transm"},{"key":"3150_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","volume":"88","author":"A McGarry","year":"2017","unstructured":"McGarry A, McDermott M, Kieburtz K et al (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:152\u2013159","journal-title":"Neurology"},{"key":"3150_CR26","doi-asserted-by":"publisher","first-page":"8755","DOI":"10.1074\/jbc.R100062200","volume":"277","author":"DB Jump","year":"2002","unstructured":"Jump DB (2002) The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277:8755\u20138758","journal-title":"J Biol Chem"},{"key":"3150_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","volume":"65","author":"BK Puri","year":"2005","unstructured":"Puri BK, Leavitt BR, Hayden MR et al (2005) Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65:286\u2013292","journal-title":"Neurology"},{"key":"3150_CR28","first-page":"1582","volume":"65","author":"Huntington Study Group TREND-HD Investigators","year":"2008","unstructured":"Huntington Study Group TREND-HD Investigators (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582\u20131589","journal-title":"Arch Neurol"},{"key":"3150_CR29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1460-9568.2006.04686.x","volume":"23","author":"Z Mao","year":"2006","unstructured":"Mao Z, Choo YS, Lesort M (2006) Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington\u2019s disease knock-in striatal cells. Eur J Neurosci 23:1701\u20131710","journal-title":"Eur J Neurosci"},{"key":"3150_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","volume":"1175","author":"J Hu","year":"2009","unstructured":"Hu J, Matsui M, Corey DR (2009) Allele-selectiveinhibitionofmutanthuntingtinbypeptidenucleicacid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann NY Acad Sci 1175:24\u201331","journal-title":"Ann NY Acad Sci"},{"key":"3150_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox DB, Platt RJ, Zhang F (2015) Therapeutic genome editing: pros- pects and challenges. Nat Med 21:121\u2013131","journal-title":"Nat Med"},{"issue":"7","key":"3150_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397\u2013405","journal-title":"Trends Biotechnol"},{"key":"3150_CR33","first-page":"244e251","volume":"3","author":"L Cai","year":"2016","unstructured":"Cai L, Fisher AL, Huang H et al (2016) CRISPR-mediated genome editing and human diseases. Genes Dis 3:244e251","journal-title":"Genes Dis"},{"key":"3150_CR34","doi-asserted-by":"crossref","unstructured":"Xu X, Hulshoff MS, Tan X, Zeisberg M, Zeisberg EM (2020) CRISPR\/Cas derivatives as novel gene modulating tools: possibilities and in vivo applications. Int J Mol Sci 21(9):3038","DOI":"10.3390\/ijms21093038"},{"issue":"3","key":"3150_CR35","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1007\/s11033-019-04761-3","volume":"46","author":"R Kumar","year":"2019","unstructured":"Kumar R, Kaur A, Pandey A et al (2019) CRISPR-based genome editing in wheat: a comprehensive review and future prospects. Mol Biol Rep 46(3):3557\u20133569. https:\/\/doi.org\/10.1007\/s11033-019-04761-3","journal-title":"Mol Biol Rep"},{"issue":"6","key":"3150_CR36","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1007\/s11033-021-06926-5","volume":"49","author":"P Shah","year":"2022","unstructured":"Shah P, Magar ND, Barbadikar KM (2022) Current technological interventions and applications of CRISPR\/Cas for crop improvement. Mol Biol Rep 49(6):5751\u20135770. https:\/\/doi.org\/10.1007\/s11033-021-06926-5","journal-title":"Mol Biol Rep"},{"key":"3150_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fpls.2014.00302","volume":"5","author":"C Cantos","year":"2014","unstructured":"Cantos C, Francisco P, Trijatmiko KR et al (2014) Identification of \u201csafe harbor\u201d loci in indica rice genome by harnessing the property of zinc-finger nucleases to induce DNA damage and repair. Front Plant Sci 5:302","journal-title":"Front Plant Sci"},{"key":"3150_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/gt.2013.83","volume":"21","author":"W Zhang","year":"2014","unstructured":"Zhang W, Wang D, Liu S et al (2014) Multiple copies of a linear donor fragment released in situ from a vector improve the efficiency of zinc-finger nuclease-mediated genome editing. Gene Ther 21:282\u2013288","journal-title":"Gene Ther"},{"key":"3150_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","volume":"79","author":"A Klug","year":"2010","unstructured":"Klug A (2010) The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 79:213\u2013231","journal-title":"Annu Rev Biochem"},{"key":"3150_CR40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1534\/genetics.110.120717","volume":"186","author":"M Christian","year":"2010","unstructured":"Christian M, Cermak T, Doyle EL et al (2010) Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:757\u2013761","journal-title":"Genetics"},{"key":"3150_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trsl.2015.09.008","volume":"168","author":"N Savic","year":"2016","unstructured":"Savic N, Schwank G (2016) Advances in therapeutic CRISPR\/Cas9 genome editing. Transl Res 168:15\u201321","journal-title":"Transl Res"},{"key":"3150_CR42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I et al (2012) Charpentier E. A programmable dual-RNA-guided DNA endonucleasein adaptive bacterial immunity. Science 337:816\u2013821","journal-title":"Science"},{"key":"3150_CR43","first-page":"689","volume":"3","author":"S Abad-Sojos","year":"2018","unstructured":"Abad-Sojos S, Torres O, Ord\u00f3\u00f1ez KL (2018) Application of the technique CRISPR\/Cas9 in the reduction and permanent inactivation of Huntington\u2019s disease.Aplicaci\u00f3n de la t\u00e9cnica CRISPR \/ Cas9 en la reducci\u00f3n e inactivaci\u00f3n permanente de la enfermedad de Huntington. News Views 3:689\u2013691","journal-title":"News Views"},{"issue":"3","key":"3150_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/biotech10030014","volume":"10","author":"K Tavakoli","year":"2021","unstructured":"Tavakoli K, Pour-Aboughadareh A, Kianersi F et al (2021) Applications of CRISPR-Cas9 as an advanced genome editing system in life sciences. BioTech (Basel) 10(3):14. https:\/\/doi.org\/10.3390\/biotech10030014","journal-title":"BioTech (Basel)"},{"issue":"20","key":"3150_CR45","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim K-H, Chao MJ et al (2016) Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25(20):4566\u20134576","journal-title":"Hum Mol Genet"},{"key":"3150_CR46","doi-asserted-by":"publisher","first-page":"28420","DOI":"10.1038\/srep28420","volume":"6","author":"SM Heman-Ackah","year":"2016","unstructured":"Heman-Ackah SM, Bassett AR, Wood MJ (2016) Precision modulation of neurodegenerative disease-related gene expression in human iPSC- derived neurons. Sci Rep 6:28420","journal-title":"Sci Rep"},{"key":"3150_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","volume":"8","author":"X Xu","year":"2017","unstructured":"Xu X, Tay Y, Sim B et al (2017) Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient- derived induced pluripotent stem cells. Stem Cell Rep 8:619\u2013633","journal-title":"Stem Cell Rep"},{"issue":"5","key":"3150_CR48","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1007\/s11033-021-06479-7","volume":"48","author":"K Prasad","year":"2021","unstructured":"Prasad K, George A, Ravi NS et al (2021) CRISPR\/Cas based gene editing: marking a new era in medical science. Mol Biol Rep 48(5):4879\u20134895. https:\/\/doi.org\/10.1007\/s11033-021-06479-7","journal-title":"Mol Biol Rep"},{"key":"3150_CR49","doi-asserted-by":"crossref","unstructured":"Dai WJ, Zhu LY, Yan ZY, Xu Y, Wang QL, Lu XJ (2016) CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Mol Ther Nucleic Acids 5(8):e349","DOI":"10.1038\/mtna.2016.58"},{"issue":"6","key":"3150_CR50","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/MOT.0000000000000244","volume":"20","author":"MG Angelos","year":"2015","unstructured":"Angelos MG, Kaufman DS (2015) Pluripotent stem cell applications for regenerative medicine. Curr Opin Organ Transplant 20(6):663\u2013670. https:\/\/doi.org\/10.1097\/MOT.0000000000000244","journal-title":"Curr Opin Organ Transplant"},{"issue":"1","key":"3150_CR51","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11033-021-06832-w","volume":"49","author":"S Dilip Kumar","year":"2022","unstructured":"Dilip Kumar S, Aashabharathi M, KarthigaDevi G et al (2022) Insights of CRISPR-Cas systems in stem cells: progress in regenerative medicine. Mol Biol Rep 49(1):657\u2013673. https:\/\/doi.org\/10.1007\/s11033-021-06832-w","journal-title":"Mol Biol Rep"},{"issue":"7","key":"3150_CR52","doi-asserted-by":"publisher","first-page":"7087","DOI":"10.1007\/s11033-022-07519-6","volume":"49","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huang C, Zhao W (2022) Recent advances of the biological and biomedical applications of CRISPR\/Cas systems. Mol Biol Rep 49(7):7087\u20137100. https:\/\/doi.org\/10.1007\/s11033-022-07519-6","journal-title":"Mol Biol Rep"},{"key":"3150_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/WCO.0000000000000116","volume":"27","author":"SD Kim","year":"2014","unstructured":"Kim SD, Fung VS (2014) An update on Huntington\u2019s disease: from the gene to the clinic. Curr Opin Neurol 27:477\u2013483","journal-title":"Curr Opin Neurol"},{"key":"3150_CR54","doi-asserted-by":"crossref","unstructured":"De Masi C, Spitalieri P, Murdocca M, Novelli G, Sangiuolo F (2020) Application of CRISPR\/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Hum Genomics 14(1):25","DOI":"10.1186\/s40246-020-00276-2"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-022-03150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-022-03150-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-022-03150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:28:12Z","timestamp":1744208892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-022-03150-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3150"],"URL":"https:\/\/doi.org\/10.1007\/s12035-022-03150-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author, SSA, NA, AA and IA have read and approved the final manuscript for submission. We confirm the figures are original for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}